Product Description
Mechanisms of Action: Gene Therapy,VEGF
Novel Mechanism: Yes
Modality: Gene Therapy
Route of Administration: Intraocular,Ophthalmic
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Chengdu Jinweike Biotechnology Co., Ltd.
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for JWK-001](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CTR20241792 | N/A |
Unknown |
Neovascular age-related macular degeneration |
None |